Equities analysts expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to announce earnings per share (EPS) of ($0.15) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.13). Aevi Genomic Medicine reported earnings of ($0.13) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.4%. The firm is scheduled to report its next earnings results on Tuesday, March 12th.
On average, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.53). For the next financial year, analysts anticipate that the firm will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.51) to $0.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last issued its earnings results on Thursday, November 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03.
Several equities research analysts recently issued reports on GNMX shares. ValuEngine lowered shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, December 20th. JMP Securities lowered shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd.
An institutional investor recently raised its position in Aevi Genomic Medicine stock. Vanguard Group Inc increased its holdings in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 986,590 shares of the biotechnology company’s stock after buying an additional 16,138 shares during the quarter. Vanguard Group Inc owned about 1.52% of Aevi Genomic Medicine worth $1,214,000 at the end of the most recent reporting period. 19.61% of the stock is currently owned by institutional investors.
Shares of NASDAQ:GNMX opened at $0.22 on Wednesday. Aevi Genomic Medicine has a 12-month low of $0.17 and a 12-month high of $2.65.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
See Also: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.